Index

Note: Page numbers in *italics* refer to Figures; those in **bold** to Tables

acute pancreatitis
  - causes, 34
  - definition, 34, 132
  - mild, 132–3
  - modified Glasgow/Imrie Criteria, 132, 133
  - severe (SAP), 133
α₂-Adrenergic agonist (Clonidine), 21
agouti-related peptide (AgRP), 48, 49
AgRP see agouti-related peptide (AgRP)
AH see alcoholic hepatitis (AH)
AIH see autoimmune hepatitis (AIH)
alanin aminotransferase (ALT), 38, 290, 291
alcohol
  - colorectal cancer (CRC), 257
  - gallstone development, 267
  - gastro-oesophageal reflux disease (GORD), 107
  - hepatitis C virus (HCV), 286
  - irritable bowel syndrome (IBS), 236
liver disease and nutrition
  - AH see alcoholic hepatitis (AH)
  - alcoholic cirrhosis, 282
  - acute Liver Disease, 281
  - fibrosis, 282
  - steatosis-fatty liver, 281–2
alcoholic cirrhosis, 282
alcoholic hepatitis (AH)
  - clinical features, 280
  - nutritional therapy
    - alcohol, 280
    - antioxidants, 281
  - nutritional assessment and goals, 281
  - nutrition support, 280–281
  - oral and enteral nutrition, 280
  - vitamins, 281
  - undernutrition
    - pathogenesis, 280
    - prevalence and effects, survival, 280
alcoholic liver disease (ALD), 281, 282
  - ALD see alcoholic liver disease (ALD)
alcoholic cirrhosis, 282
α₂-Adrenergic agonist (Clonidine), 21
alcohol
  - colorectal cancer (CRC), 257
  - gallstone development, 267
  - gastro-oesophageal reflux disease (GORD), 107
  - hepatitis C virus (HCV), 286
  - irritable bowel syndrome (IBS), 236
liver disease and nutrition
  - AH see alcoholic hepatitis (AH)
  - alcoholic cirrhosis, 282
  - acute Liver Disease, 281
  - fibrosis, 282
  - steatosis-fatty liver, 281–2
  - nutritional therapy
    - alcohol, 280
    - antioxidants, 281
    - nutritional assessment and goals, 281
    - nutrition support, 280–281
    - oral and enteral nutrition, 280
    - vitamins, 281
    - undernutrition
      - pathogenesis, 280
      - prevalence and effects, survival, 280
  - alcoholic cirrhosis, 282
  - alcoholic hepatitis (AH)
    - clinical features, 280
    - nutritional therapy
      - alcohol, 280
      - antioxidants, 281
    - nutritional assessment and goals, 281
    - nutrition support, 280–281
    - oral and enteral nutrition, 280
    - vitamins, 281
    - undernutrition
      - pathogenesis, 280
      - prevalence and effects, survival, 280
  - alcoholic liver disease (ALD), 281, 282
  - ALD see alcoholic liver disease (ALD)
  - alkaline phosphatase (ALP), 38
allergy
  - benzoates, 96
  - food, 237–8
  - milk, 203
  - oesophageal mucosa, 102
  - OFG see orofacial granulomatosis (OFG)
  - six food elimination diet (SFED), 103
amino acids
  - aromatic, 106, 300–301
  - elemental diets, 193
  - branched-chain amino acids (BCAA), 300, 304, 311
  - ghrelin, 51–2
  - pancreatic polypeptide, 50
  - transamination, 37
amylose, 4, 23, 33, 34, 149, 236
anaemia
  - chronic disease, 185
  - hepatitis C virus (HCV), 287
  - inflammatory bowel disease (IBD), 185
  - iron deficiency, 23, 25, 161, 162, 185
  - macrocytic, 23
  - malabsorption, 5
  - treatment, 186
anorexia
  - disease related, 115, 193, 301, 302, 305
  - and gastric cancer, 121, 124
anthropometry
  - alcoholic hepatitis (AH), 280
  - International Society for the Advancement of Kinanthropometry (ISAK) methods, 281
  - irritable bowel syndrome (IBS), 233
  - upper arm, 299, 305
  - anti-motility agents, 212

© 2014 John Wiley & Sons, Ltd. Published 2014 by John Wiley & Sons, Ltd.
antioxidants
and pain, chronic pancreatitis (CP), 136–7
inflammatory bowel disease (IBD), 183, 185
therapy, 137

appetite regulation
cholecystokinin, 51
ghrelin, 51–2
glucagon-like peptide 1
gut neuroendocrine system
oxyntomodulin, 51
pancreatic polypeptide, 50
peptide tyrosine-tyrosine
ARC see arcuate nucleus (ARC)
arcuate nucleus (ARC), 48
arginine, 113, 122, 123, 258, 304
artificial GI tract, 215–16
ascites
dietary management
fluid, 304
muscle atrophy, 305
protein and energy, 305
sodium, 304–5
disease-related anorexia and intake, 301
nutritional consequences, 301
aspartate aminotransferase (AST), 38, 290
AST see aspartate aminotransferase (AST)
autoimmune hepatitis (AIH)
dietary management, 284–5
insulin resistance, 285
nutritional consequences, 284
Barrett's oesophagus, 8, 69, 111
bile
acid-induced diarrhoea, 196
bile acid malabsorption (BAM), 269
canaliculi, 36
cholesterol saturation, 267, 268
faecal excretion, 58
formation, 37
ingested lipids, 156
malabsorption study, 24–5
sequestrants, 269
synthetic bile acid, 212
bile duct
bile canaliculi, 36
damage, 38
gallstones, 269
injury, 269
intra-and extrahepatic, 273
bilirubin, 37, 38, 274
body composition
inflammatory bowel disease (IBD), 180–181
nutritional assessment, 297
bone health
calcium and vitamin D supplementation, 276
chronic pancreatitis (CP), 137
Crohn's disease, 182
inflammatory bowel disease (IBD), 181–2
bone mineral density (BMD)
bone loss, 314
celiac patients, 162
vitamin K supplementation, 275
bone mineralisation, 181–2
Bravo® delivery system, 12
bulimia, 50
cachexia
alcoholic hepatitis (AH), 281
assessment, 219
cancer cachexia, 121, 141
caffeine, 107, 235, 267
calcium
absorption, 137
in bovine milk, 207
channel blockers, 13
faecal losses, 148
gastrin secretion, 106
malabsorption, 274
supplementation, 275, 276
calprotectin, 152
cancer see also gastric cancer; oesophageal
cancer
colorectal see colorectal cancer (CRC)
gastric, 18, 67
GI tract-related, 67
oesophageal, 69
pancreatic see pancreatic cancer (PC)
primary biliary tract, 39
carbohydrates
component molecules, 72
dietary, classification, 73
fermentable, 236–7
groups, 171
intake and Crohn's disease, 172
loading, CRC patients, 259
malabsorption, 148
prebiotics 87–92
short-chain fermentable see short-chain fermentable
carbohydrates
CD see Crohn's disease (CD)
CF see cystic fibrosis (CF)
CFTR see cystic fibrosis transmembrane conductance
regulator (CFTR)
Challacombe dry mouth scale, 4
cholecystokinin (CCK), 23, 36, 48, 49, 51, 266, 267
cholelithiasis, 152
chronic pancreatitis (CP)
antioxidants and pain, 136–7
bone health, 137
oral nutritional support, 136
pancreatic exocrine insufficiency (PEI), 136
pancreatic rest, 137
Index

parental nutrition (PN), 137
vitamin A deficiency, 137
chymotrypsin, 23, 33, 34
cinnamon and benzoate-free diet, OFG
chocolate, 99
dietary guidance, 97, 98, 98
flavourings, 98–9
history, 96
immunopathological mechanisms, 96
oral medicines, 99
patch testing, 97
sources, 96–7, 97, 98
soya, 99
tomatoes, 99
cirrhosis
alcoholic, 282
metabolic changes, 296–7, 298
PBC see primary biliary cirrhosis (PBC)
codeine phosphate, 212
celiac disease
aetiopathogenesis and prevalence, 160–161
clinical features, 161, 161
diagnosis
HLA DQ2/DQ8, 161–2
non-coeliac gluten sensitivity (NCGS), 162
serological testing, 161
diet, special aspects
modernisation, 160
bone mineral density, 162
diabetic patients, 163
functional hypoplasmenism, 162
obesogenic environment, 163
population-based studies, 162
dietary causes, 162
glucagon-like peptide 1, 50–51
oral ulceration, 6
treatment
gluten-free diet (GFD), 160, 164–5
gluten, 163
oats, 163–4
coffee, 98, 107, 195, 205, 228, 253, 288
colon
defaecation, 30–31
embryology, 28
treatment
defaecation, 30–31
digestion and absorption, 30
intestinal contents propulsion, 29–30
water and electrolyte homeostasis, 30
measurement and assessment, function
manometry, 31
radiopaque marker studies, 31
scintigraphy, 31
neuronal innervation, 29
structure
ascending colon, 28
caecum, 28
hastru, 29
sections, 28
sigmoid colon, 29
vascular supply, 29
colon cancer
fibre, protection, 67, 68
ghrelin serum concentrations, 52
obesity, 256–7
colorectal cancer (CRC)
alcohol, 257
diets, 255–6
fibre, protection, 67, 68
incidence, 255
medical treatment, 260
non-starch polysaccharides, 257
nutritional status
fasting guidelines and carbohydrate loading, 259
immune-enhancing nutrition, 258–9
postoperative nutrition, 259–60
preoperative nutritional status, 258
surgical treatment, 257–8
obesity, 256–7
red and processed meat, 256
short-chain fatty acids (SCFA), 67, 68
symptoms, 255
‘Westernised’ diets, 255
colostomy
dietary management
constipation, 221
diarrhoea, 221
double barrel, 218
end, 218
formation, nutritional consequences, 219, 220–221
loop, 218
complicated diverticulitis, definition, 244
constipation
causation factors
demographics, 249–50
fluid, 250
non-starch polysaccharides, 250
colonic inertia/slow transit, 249
dietary effects, 250
dietary treatments
non-starch polysaccharides, 251
probiotics and prebiotics, 251, 252, 253
functional constipation (primary/idiopathic), 249, 250
normal transit, 249
outlet delay, 249
secondary constipation (organic constipation), 249
contraction
antropyloroduodenal, 15
circular colonic muscle, 31
gallbladder, 23, 36, 37, 51, 266–8
periodical stomach wall, 16
CP see chronic pancreatitis (CP)
CRC see colorectal cancer (CRC)
Crohn’s disease (CD) see also inflammatory bowel disease (IBD)
characteristics, 170
genetic and non-genetic factors, 176, 176
genetic factors, 170
non-starch polysaccharide (NSP) intake, 172
and orofacial granulomatosis, 6
postprandial CCK concentration, 51
prebiotics, 90
primary mediators, inflammation, 170
protein intake, 173
risk factors, 175–6
small bowel, 25, 50
and ulcerative colitis (UC), 169
vitamin E intake, 171
cyclic vomiting syndrome, 18

cystic fibrosis (CF)
associated liver disease, 152
causation factors
  cystic fibrosis transmembrane conductance regulator (CFTR), 147, 148
  pancreatic enzymes deficiency, 148
  pancreatic insufficiency (PI), 148
co-morbidities, 152
dietary effects
  carbohydrate malabsorption, 148
  essential fatty acid (EFA) deficiency, 148
  fat-soluble vitamin deficiencies, 148
dietary management
  enzyme dosage, 150–151
  enzyme preparations, 149
  pancreatic enzyme replacement therapy (PERT), 148, 149
  starting doses, fat-soluble vitamins, 148, 149
  timing, pancreatic enzymes, 149–50
distal intestinal obstruction syndrome (DIOS), 151
  fibrosing colopathy, 151
  life expectancy, 147
  prevalence, 147
cystic fibrosis transmembrane conductance regulator (CFTR)
  duct obstruction, 148
  mutations, 147, 149
  pancreatic enzyme replacement therapy (PERT), 149

DD see diverticular disease (DD)
decompensated liver disease and nutrition
ascites see ascites
dietary causes and effects
  cirrhosis, metabolic changes, 296–7, 298
dry weight, 299, 299
  hand grip strength, 299
  nutritional assessment, 297, 299

nutritional requirements, 299–300, 300
nutrition screening, 299
upper arm anthropometry, 299
dietary management
  eating pattern, 302–3
  enteral nutrition, 302
  oral nutritional support, 302
  parenteral nutrition, 302
delayed puberty, 182
dental disease
  brushing and flossing, 4
caries, 5
  non-carious tooth surface loss, 5
  periodontal disease, 5
  plaque, 4–5
DEXA see dual-energy X-ray absorptiometry (DEXA)
diabetes
  adult type 1 diabetes patients, 163
  brittle, 284
celiac disease detection, 163
  endocrine insufficiency, 34
  exenatide and liraglutide, treatment, 50
  gastroparesis, 17
  non-alcoholic fatty liver disease (NAFLD), 290, 291
  normoglycaemia maintenance, 128
diarrhoea
  antibiotic-associated diarrhoea (AAD), 41, 44
  excess bile acids, 25
  prebiotics, 90, 91
  small bowel tumours, 26
DIOS see distal intestinal obstruction syndrome (DIOS)
distal intestinal obstruction syndrome (DIOS), 151
diverticular disease (DD)
definition, 244
dietary effects, 245
dietary fibre/NSP
  high-meat diets, 244
  low-fibre diet, 243–4
dietary management
  dietary fibre, 245–6
  medical management, 246–7
  probiotics, 247
fat, 245
pathogenetic events, 243, 244
diverticulitis/diverticulosis, 218, 244, 245–7, 251
dual-energy X-ray absorptiometry (DEXA), 136, 137, 181
ductal adenocarcinoma, 35, 140
dumping syndrome, 115, 124
dysphagia
  oesophageal food bolus obstruction, 101
  side-effects, 113
efferent, 33, 48
elastase
    faecal, 24, 34
    measurement, 34
elemental diet
    Emsogen, 158
    lymphangiectasia treatment, 158
elimination diet, 102, 103, 194
EN see enteral nutrition (EN)
endomysial antibodies (EMA), 161
enhanced recovery after surgery (ERAS) programme
    colorectal surgery, 258
    identification and treatment, undernutrition, 113
    immunonutrition, 113
    perioperative nutrition, 220
    preoperative carbohydrate loading, 113–14
enteral nutrition (EN)
    active Crohn’s disease, treatment
        adjunctive therapy, undernutrition, 193, 193–4
        adults, 191
        in children, 192–3
        guidelines, 191, 192
        maintenance of remission, 194
        underlying mechanisms, 193
    fat malabsorption, 269
    feed formulation, 134
    gastroparesis, 129
    nasogastric vs. nasojejunal feeding, 134
    oesophageal chemoradiation, 112
    oral nutritional supplements, 214–215, 280, 301, 302
    and PN, 114
    postoperative recovery phase, 123
    probiotics, 134–135
    ulcerative colitis (UC), 197
entocutaneous fistula, dietary management, 215
EoE see eosinophilic oesphagitis (EoE)
EORTC see European Organisation for Research and Treatment of Cancer (EORTC)
eosinophilic oesophagitis (EoE)
    causation, 102
    definition, 101
    diagnosis, 102
    dietary effects, 102
    history, 102
    symptoms, 101
    treatment
        diet, 102–3
        dilation, 103
        drugs, 103
EPIC study see European Prospective Investigation into Cancer and Nutrition (EPIC) study
essential fatty acid deficiency (EFAD), 215
European Organisation for Research and Treatment of Cancer (EORTC), 123
European Prospective Investigation into Cancer and Nutrition (EPIC) study, 118
exclusion diets
    Crohn’s disease, 194
    irritable bowel syndrome (IBS), 238
    LOFFLEX exclusion diet, 194, 195
    remission, 194
exocrine insufficiency, pancreatic, 34, 136, 141
faecal fat, 24, 34, 151, 187, 269
fats
    inflammatory bowel disease (IBD), 172–3
    natural source, 172
fermentable oligo-, di-and monosaccharides and polyols (FODMAPs) 74–76
    coeliac disease, 165
    content of foods, 77–79
    ileostomy patients, 223–4
    inflammatory bowel disease (IBD), 195, 197–8
    irritable bowel syndrome (IBS), 236–7
    subclassification categories, 74
    sugar malabsorption and breath tests, 79
fibre
    dietary, 57
    NSP see non-starch polysaccharides (NSP)
    physiological effects, 58, 63
    soluble, 57, 58
    fibrosing colonopathy, 151
    fibrosis, 282
    fistuloclysis, 215
FODMAPs see fermentable oligo-, di-and monosaccharides and polyols (FODMAPs)
    food allergy, 237–8
    food challenge, 235, 238
    food hypersensitivity, 229
    food intolerance, 97, 238
fructans
    health benefits, 76
    physiological effects, 76
    short-chain, 76
fructose
    intestinal absorption, 74
    malabsorption, 74
    functional constipation (primary/idiopathic), 249, 250
    functional dyskinesia, 39, 269
    functional dyspepsia, 18, 127
    functional gut disorders see irritable bowel syndrome (IBS)
galacto-oligosaccharides (GOS)
    bifidobacteria growth, 88–9
    description, 76, 79
    prebiotic properties, 88
gallbladder
cancer, 270
disease and nutrition
functional dyskinesia, 269
gallbladder cancer, 270
gallstones see gallstones
steatocholecystitis, 270
gallstones
alcohol, 267
causation factors, 265
dietary carbohydrate and fibre, 267
dietary fat and cholesterol, 266–7
non-nutritional factors, 265, 266
nutritional management
acute cholecystitis, 268
after cholecystectomy, 268–9
cholecystectomy, complications, 269
chronic cholecystitis, 268
minimising risk and asymptomatic gallstones, 268
obesity, 265, 266
physical activity, 267
prevalence, 265, 266
gamma-glutamyl transpeptidase (gamma-GT), 38
gastrectomy
distal tumours, 120
gastric cancer, 123
vitamin B12 deficiency, 124
gastric see also gastric emptying
antisecretory drugs, 212
antrum, 23
cancer see gastric cancer
function, 16–17
infection, 18
outlet obstruction, 141, 142
pacemaker cells, 127
tube necrosis, 115
gastric accommodation
barostat test, 16
magnetic resonance imaging, 16
gastric cancer
description, 18
diagnosis and staging, 120
diet, 67
ghrelin, 52
incidence and aetiology, 118–20
nutritional status
cancer cachexia, 121
gastric outflow obstruction, 121
gastro-oesophageal cancer patients, 121
lean body mass, 121
weight loss, 121
nutritional support
chemotherapy, 123
EORTC, 123
European Society of Parenteral and Enteral Nutrition guidelines, 122
evidence-based pathways, 121
surgery, 123
quality of life and nutritional status
late effects, treatment, 124
limited gastric resection, 123
palliative care, 124–5
survivorship, 125
treatment
chemotherapy and targeted therapies, 120
radiotherapy, 120–121
surgery, 120
gastric contractility, 16–17
gastric emptying
disorders, 17–18
gastric scintigraphy, 17
simple radiopaque marker test, 17
superconducting quantum interference device (SQUID) magnetometers, 17
wireless capsule pills, 17
gastric function
accommodation and sensation, 16
contractility, 16–17
emptying, 17
gastrin, 35, 106, 107, 212
gastroenteritis
acute, 18
infantile, 25
gastrointestinal microbiota
acetate, propionate and butyrate, 43
antibiotic treatment, 44
antimicrobial peptides, 43
antimicrobial substances, 42
bacterial metabolism, 43
Bifidobacterium infantis, 43
dendritic cells (DCs), 43
diet, 44
dysbiosis, 45
facultative anaerobes, 44
humans, 41, 42
hypothalamic-pituitary-adrenal axis-interactions, 43
lipopolysaccharide (LPS) toxicity, 43
lactobacilli and bifidobacteria, 41, 44
lymphoid tissues, 43
microbial infection, 44
pregnancy, 43–4
gastro-oesophageal reflux disease (GORD)
ambulatory reflux studies, 9
beverages, 107
cystic fibrosis, 152
definition, 105
determinants, 9
eating behaviour, 107
heartburn and acid regurgitation, 105
lifestyle and dietary treatments, 108
management, 107–8
meal composition, 106–7
meal volume and consistency, 105–6
obesity, 105
subclassification, 13
symptoms, 17

gastroparesis
causation factors, 127
definition, 17, 127
dietary effects, 127–8
dietary treatments
dietary therapy, 128
enteral nutrition, 129
food composition, 128–9
food consistency, 128
food volume, 129
PN, 129
investigations, 128

genetics
inflammatory bowel disease (IBD), 170
lactase persistence (LP), 203
genome-wide association studies (GWAS), 170
genomics, 41, 170, 175
ghrelin, 51–2
glucagon, 33, 35, 50–51, 212, 213
glucagon-like peptide-1 (GLP-1)
coeliac disease, 50–51
description, 50
glucagon-like peptide-2 (GLP-2), 213
 glutamine, 37, 135, 211, 213, 258, 304
 gluten
description, 160
 IBS patients, 237
 gluten-free diet (GFD), 164–5, 165
GORD see gastro-oesophageal reflux disease (GORD)
GOS see galacto-oligosaccharides (GOS)
growth
failure, 192, 193
linear, 182
small bowel bacterial overgrowth, 152
gut hormones, 33, 35, 48, 49, 49, 51, 52, 58, 212
GWAS see genome-wide association studies (GWAS)
hand grip dynamometry, 181, 299
HBV see hepatitis B virus (HBV)
HCV see hepatitis C virus (HCV)
 Helicobacter pylori, 18
hepatic encephalopathy
dietary causes, 300–301
dietary management
 branched chain amino acids, 304
 probiotics and prebiotics, 303
 protein, 303–4
 zinc, 304
hepatitis A, 285
hepatitis B virus (HBV), 285
hepatitis C virus (HCV)
alcohol, 286
anaemia, 287
Body Mass Index (BMI), 286
coffee, 288
complementary and alternative medicine, 287
dietary effects, 286
dietary management, 287
insulin resistance, 286–7
silymarin, 287
vitamins and minerals, 287
weight loss, 287
hepatobiliary tract
 bile acid and bilirubin metabolism, 37
 biliary disorders, 39
carbohydrate metabolism
cirrhosis, 39
drug and hormone metabolism, 37
gallbladder disorders, 39
hepatocellular carcinoma, 39
immunological function, 37
lipid metabolism, 37
measurement and assessment, function
 blood tests, 38
 endoscopy, 38
 imaging, 38
 interventional radiology, 38
 liver biopsy, 39
 paracetamol overdose, 39
 protein metabolism, 37
hepatocellular carcinoma (HCC)
nutritional requirements
 malnutrition, 310
 resting energy expenditure (REE), 310
 palliative treatments, nutritional consequences
 radiofrequency ablation (RFA), 310
 selective internal radiation therapy (SIRT), 310
 sorafenib, 310
 transarterial chemoembolism (TACE), 308–9
treatments, 309
hereditary haemochromatosis (HH), 294
hiatus hernia, 8, 9, 105, 107
HLA DQ2, 161, 162, 165
HLA DQ8, 161, 162, 165
home parenteral nutrition (HPN), 210–213, 215
HPN see home parenteral nutrition (HPN)
H\textsubscript{\text{2}} receptor antagonists, 151
human leucocyte antigens (HLA)
 DQ2, 161, 162, 165
 DQ8, 161, 162, 165
hydrogen breath tests, 24, 203, 230, 235, 237
hyponoalbuminaemia, 24, 156, 157
hypolactasia
 in adults, symptoms, 205–6
 secondary, 202
IBD see inflammatory bowel disease (IBD)
IBS see irritable bowel syndrome (IBS)
IgG mediated reactions, 229
ileostomy
  continent, 218
dehydration, 222
dietary management, 222–4, 223
end, 218
nutritional consequences, 221–2
temporary/loop, 218
imaging
  abdominal, 35
gastric contractility, 16
gastric emptying, 17
hepatic/biliary mass lesions, 38
pancreatic ductal anatomy, 35
small bowel, 24
immunonutrition, 113, 123
inflammatory bowel disease (IBD)
aetiology, 169
anaemia, 185–186
antioxidant status, 183, 185
body composition, 180–181
bone health, 181–2
Crohn’s disease
  complex, dietary management, 196
dietary treatments, 196
emerging treatments, 196
EN see enteral nutrition (EN)
exclusion diets, remission, 194
functional symptoms in remission, 194–5
malnutrition and maintenance,
remission, 196
omega-3 fatty acids, 196
parenteral nutrition, 194
probiotics, 195
delayed puberty, 182
dietary risk factors
  carbohydrates, 171–2
  fats and oils, 172–3
  micronutrients, 173–4
  protein, 173
dietary treatment, 198
gastrointestinal microbiota, 174–5
genetic factors, 170
immune dysregulation, 169–70
linear growth and short stature, 182
malnutrition aetiology
  altered energy/nutrient metabolism, 186–187
drug-nutrient interactions, 188
increased gastrointestinal nutrient losses, 187–8
reduced dietary intake, 187
micronutrients
  circulating concentrations, 184–185
  reduced serum concentrations, 183
  obesity, 174
  prevalence and incidence, 169
  protein energy malnutrition, 180
  ulcerative colitis see ulcerative colitis (UC)
insoluble fibre, 57, 246, 251
insulin
  beta cells, 33
  insulin-induced hypoglycaemia, 18
  preoperative carbohydrate loading, 114
  resistance
    autoimmune hepatitis (AIH), 285
    Crohn’s disease, 174
    hepatitis C virus (HCV), 286–7
    non-alcoholic fatty liver disease (NAFLD), 291
    pancreatic cancer (PC), 141
International Society for the Advancement of
  Kinanthropometry (ISAK), 281
intestinal failure (IF)
  acute intestinal failure, 210
  adaptation, 212–13
  chronic intestinal failure, 210
  enteral nutrition (EN), 214–15
  enterocutaneous fistula, dietary management, 215
  intestinal failure and short bowel, consequences, 211
  intestinal transplantation, 215–16
  jejunoileal anastomosis, dietary management, 214
  jejunostomy, dietary management of patients, 214
  micronutrient deficiencies, 215
  nutritional management, 213
  oral nutritional supplements (ONS), 214–15
  pharmaceutical management, 212
  short bowel, fluid and electrolyte management,
  211–12, 213
intestinal inflammation, 152
intestinal lymphangiectasia
  features, 156–7
  nutritional causes, 156
  nutritional effects, 157
intestinal permeability, 25, 85, 133, 170, 193, 237, 238, 258
inulin-type fructans (ITF), 88, 88, 88
iron
  absorption, 185, 188, 294
  colorectal cancer (CRC), 256
  deficiency anaemia, 23, 25, 161, 162, 185
  liver, 294
irritable bowel syndrome (IBS)
dietary effects, 233, 234, 235
dietary interventions
  alcohol, 236
  caffeine, 235
  fat, 236
  fermentable carbohydrates, 236–7
  gluten, 237
  lactose, 235
non-starch polysaccharides (NSP), 235
resistant starch (RS), 236
exclusion diets, 238
food allergy, 237–8
food hypersensitivity, 229
genetic factors
dizygotic twins, 226
interleukin (IL)-10, 227
polymorphisms, 227
serotonergic system, 226–7
gut microbiota, 229–30
inflammatory mechanisms and dietary components, 229
pharmacological food intolerance, 238
prebiotics, 90, 91, 239–40
probiotics, 238–9
psychological factors, 227
visceral hypersensitivity, 227–9
islets of Langerhan, 33
ITF see inulin-type fructans (ITF)

JCA see jejuno colic anastomosis (JCA)
jejunal feeding, 82, 114, 123, 129, 134, 137
jejuno colic anastomosis (JCA), 211, 213, 214
jejunostomy

cirrhosis, 302
complications, 114
intestinal failure (IF), 211, 214
postpyloric feeding, 114

Lactobacillus plantarum, 134, 238–9
lactose
description, 74
digesters, 202
hydrogen breath testing, 235
intolerance, 203
lactose malabsorption
breath hydrogen test, 203
dairy intakes, pros and cons, 206–7
dietary strategies, 206, 206
glucose and galactose test, 203
hypolactasia in adults, symptoms, 205–6
lactase non-persistence, 202
lactase digesters, 202
lactose intolerance, 203
milk and dairy products, consumption, 202
nutritional disadvantages, 203
primary hypolactasia, 202
lactase persistence (LP)
distribution, 203, 204
genetics, 203
natural selection and evolution, humans, 205
late evening carbohydrate, 302, 303
lipase, 15, 23, 33, 34, 143, 148, 149, 150, 151, 156
liver
biopsy, 39
diseases, 39
divisions, 36
function tests, 38
gallbladder, 36
glucose homeostasis, 36–7
hormone metabolism, 37
lipid metabolism, 37
protein metabolism, 37
vitamin E, 294

liver transplantation and nutrition
bone disease, 313–14
drug-nutrient interactions, 314
food safety post transplantation, 314–15
indications, 311, 312
metabolic syndrome post liver transplant, 313
nutritional requirements and post transplant enteral nutrition (EN), 312–13
protein catabolism, 312
nutritional status pretransplant
overweight and obesity, 311–12
undernutrition, 311
probiotics, 314
recurrence of diseases, 314
long chain triglycerides (LCT), 158, 203, 214
loperamide, 144, 212
lower oesophageal sphincter (LOS), 8, 9, 10, 11, 15, 106
lymphangiectasia
description, 155
diagnosis, 157
intestinal lymphangiectasia
lymphatic system
enlarged lymph nodes, 155
ingested lipids, 156
primary intestinal lymphangiectasia, 155

manometry
colonic, 31
high-resolution manometry (HRM), 9, 10, 11
liver
biopsy, 39
mast cells, 228, 229, 237
medium chain triglycerides (MCT), 25, 158, 213, 214, 268
microbiota see gastrointestinal microbiota
micronutrients
deficiency, 26, 27, 180, 182, 183, 215, 219
dietary recommendations, colostomy and ileostomy, 224
inflammatory bowel disease (IBD), 174, 184–5
MII-pH see multiple intraluminal impedance with pH monitoring (MII-pH)
milk
allergy, lactose intolerance, 203
and dairy products, consumption, 173, 202
thistle (silymarin), 287
mixing, 4, 17, 26, 29, 30, 149, 150
motility
antroduodenal, 16
colonic, 29–31, 235, 236, 243
disorders, 11
gastrointestinal, 114
oesophagus, 9, 12–13
mouth
cheeks, 3
dental disease see dental disease
digestion, 4
floor, 3
function, 4
gastrointestinal disease see gastrointestinal disease
gingivae, 3
lips, 3
measurement and assessment, function, 4
palate, 3
salivary glands, 4
teeth, 3
tongue, 3
MRI see magnetic resonance imaging (MRI)
multiple intraluminal impedance with pH monitoring (MII-pH), 10, 12
NCGS see non-coeliac gluten sensitivity (NCGS)
nerves, afferent
extrinsic nerves, 29
nociceptive nerves, 228
visceral afferent neuronal pathways, 228
neuroendocrine
system, appetite regulation, 48–9
tumours, 35, 140
neuropeptide Y (NPY), 48, 49, 49, 52
non-alcoholic fatty liver disease (NAFLD)
causes, 291, 291
central obesity, 290, 291
dietary management
bariatric surgery, 293

glycaemic control, 293
weight-reducing diets, 291–3, 292
hepatitis C, 293
and liver transplant, 293–4
non-alcoholic fatty liver (NAFL), 290
non-alcoholic steatohepatitis (NASH), 290, 292
nutritional assessment, 291
omega-3 fatty acids use, 294
physical activity, 293
prevalence, 290
risk factors, 290
stages, 290, 291
two-hit theory, 291, 292
vitamin E, 294
non-coeliac gluten sensitivity (NCGS), 162
non-IgE mediated, 237
non-starch polysaccharides (NSP)
classification, 58, 59–62
colonic microbiota, 65
colorectal cancers, 67, 68
dietary supplementation, fibre, 58
gastric cancer, 67
gastrointestinal immunity, 65
gastrointestinal structure and health, 63
GI tract-related cancers, 67
gut mucus layer, 63, 64, 65, 66
oesophageal cancer, 69
physiological effects, fibre, 58, 63
stool frequency and consistency, 65, 67
normal transit constipation, 249
NSP see non-starch polysaccharides (NSP)
obesity
colon cancer, 256–7
Crohn’s disease, 196
gallstones, 265–6
GLP-1, 51
inflammatory bowel disease (IBD), 174
inflammatory bowel disease aetiology, 174
non-alcoholic fatty liver disease (NAFLD), 293
pancreatic cancer (PC) risk, 141
sarcopenic, 121
two-hit theory, obesity-related hepatic fibrosis, 292
waist circumference levels, central, 290, 291
obstruction
biliary, 39
distal intestinal obstruction syndrome, 151
gastric outflow, 121, 123, 125
jejunostomy-related bowel, 114
oesophagogastric junction (OGJ), 27
octreotide, 158, 212, 215
oesophageal cancer
aetiology, 111
ageing population, 111
nutrition, 111
palliative setting, 115–16
treatment
chemotherapy, 112
multimodality, 111
oesophageal stenting, 115
radiotherapy, 112–13
surgery, 113–15
oesophagectomy
complications
anastomotic leak, 114
chyle leak, 115
dietary advice and quality of life, 115
gastric tube necrosis, 11
dietary advice and quality of life, 115
enteral access, 114
oesophagitis
eosinophilic see eosinophilic oesophagitis (EoE)
erosive, 13
reflux, 105
oesophagus
anti-reflux barrier, 8
co-ordinated peristaltic activity, 9
deglutitive inhibition, 8
description, 8
lower oesophageal sphincter relaxations, 9
measurement and assessment, function
ambulatory reflux studies, 9–10
manometry, 9
MII-pH, 10–12
wireless pH monitoring, 12
oesophagogastric junction (OGJ), 8, 9, 12
pathology
GORD, 13
motility, 12–13
transient lower oesophageal sphincter relaxation, 9, 11
OFG see orofacial granulomatosis (OFG)
omega-3 fatty acids, 113, 122, 123, 196, 197, 245, 294
omega-6 fatty acids, 293
oral nutritional supplements (ONS), 214–15, 258
oral rehydration, 25, 212, 222, 269
orofacial granulomatosis (OFG)
aetiology, 95
chocolate, 99
cinnamon and benzoate-free diet see cinnamon and
benzoate-free diet
cosmetics and toiletries, 99
description, 95
flavourings, 98–9
outlet delay constipation, 249
oxyntomodulin (OXM), 51
pancreas
assessments of function, 34
autonomic nervous system, 33
cystic lesions, 35
ductal adenocarcinoma, 35
diabetes, 140
diabetes mellitus, type 2, 140
diabetic foot, 129
diabetes insipidus, 136
diabetes insipidus type 1, 136
endocrine cells, 33
exocrine and endocrine functions, 33
neuroendocrine tumours, 35
pancreatitis
acute, 34
chronic, 34–5
structural assessment, 34
pancreatic cancer (PC)
causation factors
alcohol, 140
cancer-protective effects, flavonols, 141
red meat, 141
smoking, 140
type 2 diabetes, 140
dietary effects
CC, 141
chemotherapy and radiotherapy, 142
gastric outlet obstruction, 142
partial pancreaticoduodenectomy, 142
PEI, 141
dietary management, 142–4
ductal adenocarcinoma, 140
incidence, 140
pancreatic enzyme replacement therapy (PERT)
aims, 149
efficacy, 151
guidelines, 150
recommended doses, 150, 151
pancreatic exocrine insufficiency (PEI), 34, 136, 141
pancreatic insufficiency
cystic fibrosis, 148, 149
exocrine, 148
faecal elastase measurement, 34
pancreatic enzyme replacement therapy, 269
vitamin D deficiency, 137
pancreatic polypeptide (PP), 48, 49, 50–51
pancreatitis
acute see acute pancreatitis
causes, 132
chronic, 34–5
CP see chronic pancreatitis (CP)
enteral nutrition (EN)
feed formulation, 134
nasogastric vs. nasojejunal feeding, 134
probiotics, 134–5
parenteral nutrition (PN)
fish oils, 135
glutamine, 135
post-discharge care, 135
parenteral nutrition (PN)
chronic pancreatitis, 137
gastroparesis, 129
ulcerative colitis (UC), 197
PC see pancreatic cancer (PC)
PEI see pancreatic exocrine insufficiency (PEI)

peptide
agouti-related peptide (AgRP), 48, 49
antimicrobial, 42, 43, 175
defensins, 85
ghrelin, 51–2
GLP-1, 50–51
GLP-2, 213
pancreatic polypeptide, 50
peptide tyrosine-tyrosine (PYY)
cerebrospinal fluid (CSF), 50
forms, 49
gluten-free diet, 50
PYY3–36 concentrations, 49

peristalsis, 8, 9, 10, 11, 13, 45

PERT see pancreatic enzyme replacement therapy (PERT)

pharmacological food intolerance, 238
pH monitoring, 9, 10, 12, 106, 107
phospholipase A2, 33
PN see parenteral nutrition (PN)
polymeric diet, 212, 220
polyols, 74, 76
portal hypertension, 38, 133, 152, 273, 282
prebiotics
  carbohydrates
    component molecules, 72
dietary, classification, 73
characteristics, 87
classes, 88
clinical applications
  Crohn’s disease, 90
  GI infectious diarrhoea, 90, 91
  IBS, 90, 91
physiological effects, 89
definitions, 87
galactans, 87
gastrointestinal microbiota, 88–9
habitual long-term diet, 87
irritable bowel syndrome (IBS), 239–40
inulin type fuctans (ITF), 88
lactulose, 88
properties, 88
preservatives, 18, 97, 99, 238
primary biliary cirrhosis (PBC)
  causation factors, 273
  cholestasis, 273
  dietary management
    co-existing autoimmune diseases, 275
    fat restriction, 275
    fat-soluble vitamins and minerals, 275,
    276, 277–8
lifestyle advice, 276

primary sclerosing cholangitis (PSC)
coa-existing autoimmune diseases, 274–5
disease symptoms, 274
hyperlipidaemia and xanthoma, 274
liver disease (hepatic osteodystrophy), 273–4
malabsorption, 274
malnutrition, 273
medication side-effects, 274
primary sclerosing cholangitis (PSC), 273
probiotics
  animal models, 85
  antimicrobial activities, 85
  commercial production, 83
defensins, 85
definition, 81
dendritic cells, 84
diverticular disease, 247
evaluation, 81, 82
irritable bowel syndrome (IBS)
  anti-inflammatory, 238
  Bifidobacterium animalis DN 173010, 239
  Bifidobacterium bifidum MIMBb75, 239
  Bifidobacterium infantis 35624, 239
  Escherichia coli DSM 17252, 239
  Escherichia coli Nissle 1917, 239
  GI transit, 238
  Lactobacillus plantarum, 238–9
  modulate visceral hypersensitivity, 238
  small intestinal permeability, 238
  VSL#3, 239
intestinal epithelial cells, 84
Lactobacillus rhamnosus, 81
microbiome, 84
micro-organism nomenclature, 81, 83
safety
  bacterial translocation, 82
  immunocompromised adults and neonates, 83
  infections, 82
  strain specificity, 83
  studies, 85
ulcerative colitis (UC), 198
vaccination trials, 84
yoghurt, 84
protein
  albumin, 24
  metabolism, 37
  protein-rich meals, 49
protein-energy malnutrition (PEM), 180, 280
protein losing enteropathy, 24, 25, 156, 158, 165
proton pump inhibitors (PPI), 108, 136, 144, 151, 212
PSC see primary sclerosing cholangitis (PSC)
pseudocyst, 35, 132, 133, 137
pylorus, 15, 15, 16, 17, 21, 121, 124, 125, 142
Index

radiofrequency ablation (RFA), 309, 310
rectal cancer, 256, 257
rectal prolapse, 152
REE see resting energy expenditure (REE)
reflux
  ambulatory reflux studies, 9–10
  chronic, 13
  dietary fibre, 106
  GORD see gastro-oesophageal reflux disease (GORD)
  oesophagitis, 105
refractory coeliac disease (RCD), 165
resistant starch, 61, 73, 87, 236
resting energy expenditure (REE), 186, 187, 301, 305, 310
RFA see radiofrequency ablation (RFA)
ribonucleic acid, 113, 123
rumination, 18
salicylates, 238
SCFA see short-chain fatty acids (SCFA)
secondary constipation (organic constipation), 249
secretors, 211
SeHCAT see synthetic bile acid scan (SeHCAT)
selective internal radiation therapy (SIRT), 310
semi-elemental formulae, 214
sensation
  and gastric accommodation, 16
  oral mucosa, 5
  taste, 3, 313
  thirst, 253
severe acute pancreatitis (SAP)
  complications, 133
  enteral nutrition (EN), 134
  fish oils, 135
  pancreatic parenchyma, 135, 141
  persistent negative nitrogen balance, 133
  probiotics, 134
SFED see six food elimination diet (SFED)
short bowel
  citrulline concentration, 211
  dietary treatment, 213, 213
  fluid and electrolyte balance, 211–12
  micronutrients, 215
  ‘secretors’ and ‘absorbers’, 211
  syndrome, 26, 27, 65, 196
short-chain fatty acids (SCFA)
  AMP generation, 43
  colonic blood flow, 58
  health-promoting effects, 57
  production, 30, 63
  properties, 63
short-chain fermentable carbohydrates
  dietary carbohydrates classification, 73
  FODMAPs, 74–9
  gastrointestinal effects, 72
Silymarin, 287
SIRT see selective internal radiation therapy (SIRT)
six food elimination diet (SFED), 103
small bowel bacterial overgrowth, 152
small intestine/small bowel
  duodenum, 21, 22, 23
  enterocytes, 21
  investigation
    bile malabsorption study, 24–5
    blood tests, 23–4
    endoscopy, 24
    hydrogen breath tests, 24
    malabsorption tests, 24
    radiology, 24
  jejunum and ileum, 22, 23
pathology
  infection, 25
  inflammation, 25
  short bowel syndrome, 27
  tumours, 26–7
  villous atrophy, 25
physiology and function
  gastric antrum, 23
  lipids and carbohydrates, 23
  proteins and peptides, 23
  solid foods, 23
  structure, 22
  substructures, 21
  tubular intestinal glands, 21
sodium
  ascites management, 304–5
  jejunostomy effluent, 211–12
  soluble fibre, 57, 58, 59, 67, 113, 212, 235, 246, 251, 267
  somatostatin, 34, 35, 37, 212
  sorbitol, 62, 72, 73, 74, 75, 76, 77, 79, 236
  sphincter of Oddi, 33, 266
  steatocholecystitis, 270
  steatorrhoea, 25, 26, 133, 134, 136, 137, 143, 144, 148, 157, 260, 269, 274, 276, 282, 296
  steatosis-fatty liver, 281–2
stomach
  acute gastroenteritis, 18
  anatomical regions, 15
  cyclic vomiting syndrome, 18
  disorders, gastric emptying, 17–18
  functional dyspepsia, 18
  gastric cancer, 18
  gastric emptying, 15
  gastric function see gastric function
  GORD see gastro-oesophageal reflux disease (GORD)
Helicobacter pylori, 18
intra gastric pylori, 18
intragastric pylori, 18
rumination, 18
stomas and nutrition
colostomy
dietary management, 221
double barrel, 218
double barrel, 218
end, 218
formation, nutritional consequences, 219, 220–221
loop, 218
formation, conditions, 218, 218
ileostomy
colon, 218
dehydration, 222
dietary management, 222–4, 223
dietary management, 222–4, 223
end, 218
formation, nutritional consequences, 221–2
formation, conditions, 218
formation, conditions, 218
formation, conditions, 218
formation, conditions, 218
formation, conditions, 218
ileostomy
continent, 218
dehydration, 222
dietary management, 222–4, 223
dietary management, 222–4, 223
end, 218
formation, nutritional consequences, 221–2
temporary or loop, 218
perioperative nutrition
and enhanced recovery after surgery, 220
postoperative complications, 220
preoperative nutritional status
cancer cachexia, 219
inflammatory bowel disease (IBD), 219
sugar alcohols, 74, 76
synthetic bile acid scan (SeHCAT), 24–5
TACE see transarterial chemoembolism (TACE)
teduglutide, 213
tissue transglutaminase (tTG), 161
transarterial chemoembolism (TACE), 309–10
transit time, 30, 31, 44, 45, 65, 67, 123, 124, 151, 205, 207, 211, 212, 214, 245, 246, 249, 250
tricep skinfold thickness (TST), 299
trypsin, 23, 33
ulcerative colitis (UC)
dietary management, 197
dietary management, 197
diet, remission, 197–8
enteral and parenteral nutrition, 197, 197
oral features, 6
probiotics, 198
PYY concentrations, 50
undernutrition
alcoholic hepatitis (AH), 280
delayed puberty, 182
inflammatory bowel disease (IBD), 183, 193
identification and treatment, ERAS, 113
liver diseases, 39
liver transplant recipients, 311
variceal bleeding, 38, 296, 302
varices, 38, 133, 276, 282, 296, 302
vascular endothelial growth factor (VEGF), 155, 156
vasoactive amines, 238
VEGF see vascular endothelial growth factor (VEGF)
villous atrophy
coeliac disease, 25
malabsorption, 25, 26
viral hepatitis
hepatitis A, 285
hepatitis B, 285
hepatitis C see hepatitis C virus (HCV)
visceral hypersensitivity
central sensitisation, 228–9
description, 227–8
nutrient intake, 228
peripheral sensitisation, 228
psychosocial stress, 228
vitamins
deficiency
vitamin A, 137, 148, 277
vitamin D, 26, 137, 143, 148, 314
vitamin E, 26, 143, 148
vitamin K, 26, 148
vitamin A, 5, 22, 23, 26, 108, 124, 162, 174, 188, 213, 222, 224
vitamin B1, 22, 26, 184, 281
vitamin B2, 22, 281
vitamin B6, 26, 174, 184, 219, 270, 281
vitamin B12, 5, 22, 23, 26, 37, 108, 124, 162, 174, 184, 185, 213, 219, 222, 224, 281
vitamin C, 22, 26, 171, 184–5, 267, 287, 294
Whipple’s
disease, 25, 26
procedure, 142
zinc, 26, 63, 148, 173, 174, 219, 281, 287, 301, 304, 313